Curcumin Sensitizes Chemotherapeutic Drugs Via Modulation of PKC, telomerase, NF-κB and HDAC in Breast Cancer

• Murthy NS , ChaudhryK, NadayilD, AgarwalUK, SaxenaS. Changing trends in incidence of breast cancer: Indian scenario. Indian J. Cancer46, 73–74 (2009).
   PubMedGoogle Scholar
• Ali S , OliviaA, LiY, PettitGR, SarkarFJ, PhilipPA. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemother. Pharmacol.52, 235–246 (2003).
   PubMed Web of Science ®Google Scholar
• Aggarwal BB , HarikumarKB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell. Biol.41(1), 40–59 (2009).
   PubMed Web of Science ®Google Scholar
• Mukherjee S , GhoshU, BhattacharyaNP, BhattacharyaRK, DeyS, RoyM. Curcumin induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol. Cell. Biochem.297, 31–39 (2007).
   PubMed Web of Science ®Google Scholar
• Al-Omar FA , NagiMN, AbdulgadirMM, Al Joni KS, Al-Majed AA. Immediate and delayed treatments with curcumin prevent forebrain ischemia-induced neuronal damage and oxidative insult in the rat hippocampus. Neurochem. Res.31, 611–618 (2006).
   PubMed Web of Science ®Google Scholar
• Aggarwal BB . Inflammation and cancer: a silent killer, is not so silent. Current Opin. Pharmacol.9, 1–4 (2009).
   PubMed Web of Science ®Google Scholar
• Aggarwal BB , SungB. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci.30(2), 85–94 (2008).
   PubMed Web of Science ®Google Scholar
• Mahmmoud YA . Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions. Br. J. Pharmacol.150(2), 200–208 (2007).
   PubMed Web of Science ®Google Scholar
• Bhandarkar SS , ArbisorJL. Curcumin as an inhibitor of angiogenesis. Adv. Exp. Med. Biol.595, 185–195 (2007).
   PubMed Web of Science ®Google Scholar
• Goel A , KunnumakkaraAB, AggarwalBB. Curcumin as “Curecumin”: From kitchen to clinic. Biochem. Pharmacol.75, 787–809 (2008).
   PubMed Web of Science ®Google Scholar
• Bianco R , MelisiD, CiardielloF, TortoraG. Key cancer cell signal transduction pathways as therapeutic targets. Eur. J. Cancer42, 290 –294 (2006).
   PubMed Web of Science ®Google Scholar
• Pan Q , BaoLW, KleerCGet al. Protein kinase Cε is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. 65(18), 8366–8371 (2005).
   PubMed Web of Science ®Google Scholar
• Lahn M , KöhlerG, SundellKet al. Protein kinase C α expression in breast cancer. Oncology (Int. J. Cancer Res. Treatment). 67(1), 1–10 (2004).
   Google Scholar
• Chakraborty S , GhoshU, BhattacharyaNP, BhattacharyaRK, RoyM. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat. Res.596, 81–90 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang J , TuY, SchneiderSS. Activation of p53, inhibition of telomerase activity and induction of estrogen receptor beta are associated with the anti-growth effects of combination of ovarian hormones and retinoids in immortalized human mammary epithelial cells. Cancer Cell Intl5, 6 (2005).
   PubMedGoogle Scholar
• Indran IR , HandeMP, PervaizS. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res.71(1), 266–276 (2011).
   PubMed Web of Science ®Google Scholar
• Choi S -H, Im E, Kang H K et al. Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells. Cancer Lett.227, 153–162 (2005).
   PubMed Web of Science ®Google Scholar
• Nishikori M . Classical and alternative NF-κB activation pathways and their roles in lymphoid malignancies. J.Clin.Exp.Hematopathol.45(1), 15–24 (2005).
   Google Scholar
• Cai C , YaoZ. Activation of NF-κB in human breast cancer and its role in cell proliferation and progression. Chin. J. Clin. Oncol.3(1), 5–10 (2006).
   Google Scholar
• Haffner MC , BerlatoC, DopplerW. Exploiting our knowledge of NF-κB signaling for the treatment of mammary cancer. J. Mammary Gland Biol. Neoplasia11, 63–73 (2006).
   PubMed Web of Science ®Google Scholar
• Biswas DK , IglehartJD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-κB) signaling in breast cancer. J. Cellular Physiol.209(3), 645–652 (2006).
   PubMed Web of Science ®Google Scholar
• Ali ZR . Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anti Cancer Drugs21(9), 805–813 (2010).
   PubMed Web of Science ®Google Scholar
• Peserico A , SimoneC. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J. Biomed. Biotechnol. 371832, DOI: 10.1155/2011/371832 (2011).
   PubMedGoogle Scholar
• Hess-Stumpp H . Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur. J. Cell. Biol.84, 109–121 (2005).
   PubMed Web of Science ®Google Scholar
• Ocker M , Schneider-StockR. Histone deacetylase inhibitor: signalling towards p21cip1/waf1. Int. J. Biochem. Cell. Biol.39, 1367–1374 (2007).
   PubMed Web of Science ®Google Scholar
• Margueron R , DuongV, CastetA, CavaillèsV. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem. Pharmacol.68(6), 1239–1246 (2004).
   PubMed Web of Science ®Google Scholar
• Henson PM , HumeDA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol.27(5), 244–250 (2006).
   PubMed Web of Science ®Google Scholar
• Martin K . Targeting apoptosis with dietary bioactive agents. Exp. Biol. Med.-231, 117–129 (2006).
   Web of Science ®Google Scholar
• Mukherjee S , BhattacharyaRK, RoyM. Targeting protein kinase C (PKC) and telomerase by phenethyl isothiocyanate (PEITC) sensitizes PC-3 cells towards chemotherapeutic drug-induced apoptosis. J. Env. Pathol. Toxicol. Oncology28(4), 269–282 (2009).
   PubMed Web of Science ®Google Scholar
• Assender JW , GeeJM, LewisI, EllisIO, RobertsonJF, NicholsonRI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol.60, 1216–1221 (2007).
   PubMed Web of Science ®Google Scholar
• Kim J , ThorneSH, SunL, HuangB, Mochly-RosenD. Sustained inhibition of PKCα reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene30(3), 323–333 (2011).
   PubMed Web of Science ®Google Scholar
• Li H , Bernard Weinstein I. Protein kinase C β enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res.66(23), 11399–11408 (2006).
   PubMed Web of Science ®Google Scholar
• Dudek AZ , ZwolakP, JasinskiPet al. Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest. New Drugs 26(1), 13–24 (2008).
   PubMed Web of Science ®Google Scholar
• Lu D , SivaprasadU, HuangJ, ShankarE, MorrowS, BasuA. Protein kinase C protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. Apoptosis12(10), 1893–1900 (2007).
   PubMed Web of Science ®Google Scholar
• Sun R , GaoP, ChenLet al. Protein kinase C {zeta} is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res. 65(4), 1433–1441 (2005).
   PubMed Web of Science ®Google Scholar
• Moon DO , KimMO, HeoMS, LeeJD, ChoiYH, KimGY. Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Archieves Pharmacol. Res.32(10), 1351–1360 (2009).
   PubMed Web of Science ®Google Scholar
• Ward RJ , AutexierC. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol. Pharmacol.68(3), 779–786 (2005).
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB , GuhaS, KrishnanS, DiagaradjaneP, GelovaniJ, AggarwalBB. Curcumin potentiateds antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis and inhibition of nuclear factor κB regulated gene products. Cancer Res.67(8), 3853–3861 (2007).
   PubMed Web of Science ®Google Scholar
• Aggarwal BB . Nuclear factor-κB: the enemy within. Cancer Cell6, 203–208 (2004).
   PubMed Web of Science ®Google Scholar
• Long L , CaoY. Down-regulation of Notch1 and NF-κB by curcumin in breast cancer cells MDA-MB-231. Chin. J. Cancer Res.20(4), 294–300 (2008).
   Web of Science ®Google Scholar
• Mabuchi S , OhmichiM, NishioYet al. Inhibition of inhibitor of nuclear factor-κB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin. Cancer Res. 10(22), 7645–7654 (2004).
   PubMed Web of Science ®Google Scholar
• Krusche CA , WuklfingP, KerstingCet al. Histone deacetylase 1 and 3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treatment 90, 15–23 (2005).
   PubMed Web of Science ®Google Scholar
• Sharma D , BlumJ, YangX, BeaulieuN, MacleodAR, DavidsonNE. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol.19(7), 1740–1751 (2005).
   PubMedGoogle Scholar
• Fan J , Yin W-J, Lu J-S et al. ER α negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol.134(8), 883–890 (2008).
   PubMed Web of Science ®Google Scholar
• Sui M , HuangY, ParkBH, DavidsonNE, FanW. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res.67(11), 5337–5344 (2007).
   PubMed Web of Science ®Google Scholar
• Tabuchi Y , MatsuokaJ, GunduzMet al. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int. J. Oncol. 34, 313–319 (2009).
   PubMed Web of Science ®Google Scholar

Websites

• World Cancer Report. International Agency for Research on Cancer. www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf
   Google Scholar
• T-test. www.physics.csbsju.edu/stats/t-test_NROW_form.html
   Google Scholar
• Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKCα expression is a marker for breast cancer aggressiveness. Mol. Cancer 9(76), (2010). www.molecular-cancer.com/content/9/1/76.
   Google Scholar